APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurometabolic Disorders

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurometabolic Disorders Industry Growth and Trends Forecast to 2032

Report ID 174016590119 December 2025114 pages

Choose your research edition.

Industry ResearchNeurometabolic Disorders Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurometabolic Disorders Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurometabolic Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurometabolic Disorders Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurometabolic Disorders Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

According to APO Research, the global Neurometabolic Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Neurometabolic Disorders market include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurometabolic Disorders market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurometabolic Disorders market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurometabolic Disorders market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurometabolic Disorders.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Neurometabolic Disorders market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurometabolic Disorders Market by Company

Amicus

Amicus Therapeutics

Biomarin

Biosidus

Dong-A Socio Group

ExSAR Corporation

Genzyme

Greencross

Greenovation Biotech

ISU Abxis

JCR Pharmaceuticals

Lixte Biotechnology

Neuraltus Pharmaceuticals

Pharming Group

Protalix

Protalix BioTherapeutics

Shire

UAB Proforma

Neurometabolic Disorders Segment by Type

Pompe Disease

Mucopolysaccharidosis VI

Gaucher’s Disease

Fabry Disease

Other

Neurometabolic Disorders Segment by Application

Oral

Parenteral

Neurometabolic Disorders Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Neurometabolic Disorders companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Neurometabolic Disorders Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Neurometabolic Disorders Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Neurometabolic Disorders Market Share by Region (2021-2026) Table 4. Global Neurometabolic Disorders Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Neurometabolic Disorders Market Share by Region (2027-2032) Table 6. Global Neurometabolic Disorders Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Neurometabolic Disorders Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Neurometabolic Disorders Market Size Share by Type (2021-2026) Table 9. Global Neurometabolic Disorders Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Neurometabolic Disorders Market Size Share Forecasted by Type (2027-2032) Table 11. North America Neurometabolic Disorders Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Neurometabolic Disorders Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Neurometabolic Disorders Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Neurometabolic Disorders Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Neurometabolic Disorders Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Neurometabolic Disorders Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Neurometabolic Disorders Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Neurometabolic Disorders Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Neurometabolic Disorders Market Size Share by Application (2021-2026) Table 24. Global Neurometabolic Disorders Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Neurometabolic Disorders Market Size Share Forecasted by Application (2027-2032) Table 26. North America Neurometabolic Disorders Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Neurometabolic Disorders Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Neurometabolic Disorders Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Neurometabolic Disorders Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Neurometabolic Disorders Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Neurometabolic Disorders Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Neurometabolic Disorders Industry Trends Table 37. Neurometabolic Disorders Industry Drivers Table 38. Neurometabolic Disorders Industry Opportunities and Challenges Table 39. Neurometabolic Disorders Industry Restraints Table 40. Global Neurometabolic Disorders Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Neurometabolic Disorders Revenue Market Share by Company (2021-2026) Table 42. Global Neurometabolic Disorders Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Neurometabolic Disorders Key Company Headquarters & Area Served Table 44. Global Neurometabolic Disorders Company, Product Type & Application Table 45. Global Neurometabolic Disorders Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Neurometabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Amicus Company Information Table 49. Amicus Business Overview Table 50. Amicus Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Amicus Neurometabolic Disorders Product Portfolio Table 52. Amicus Recent Development Table 53. Amicus Therapeutics Company Information Table 54. Amicus Therapeutics Business Overview Table 55. Amicus Therapeutics Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Amicus Therapeutics Neurometabolic Disorders Product Portfolio Table 57. Amicus Therapeutics Recent Development Table 58. Biomarin Company Information Table 59. Biomarin Business Overview Table 60. Biomarin Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Biomarin Neurometabolic Disorders Product Portfolio Table 62. Biomarin Recent Development Table 63. Biosidus Company Information Table 64. Biosidus Business Overview Table 65. Biosidus Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Biosidus Neurometabolic Disorders Product Portfolio Table 67. Biosidus Recent Development Table 68. Dong-A Socio Group Company Information Table 69. Dong-A Socio Group Business Overview Table 70. Dong-A Socio Group Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Dong-A Socio Group Neurometabolic Disorders Product Portfolio Table 72. Dong-A Socio Group Recent Development Table 73. ExSAR Corporation Company Information Table 74. ExSAR Corporation Business Overview Table 75. ExSAR Corporation Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. ExSAR Corporation Neurometabolic Disorders Product Portfolio Table 77. ExSAR Corporation Recent Development Table 78. Genzyme Company Information Table 79. Genzyme Business Overview Table 80. Genzyme Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Genzyme Neurometabolic Disorders Product Portfolio Table 82. Genzyme Recent Development Table 83. Greencross Company Information Table 84. Greencross Business Overview Table 85. Greencross Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Greencross Neurometabolic Disorders Product Portfolio Table 87. Greencross Recent Development Table 88. Greenovation Biotech Company Information Table 89. Greenovation Biotech Business Overview Table 90. Greenovation Biotech Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Greenovation Biotech Neurometabolic Disorders Product Portfolio Table 92. Greenovation Biotech Recent Development Table 93. ISU Abxis Company Information Table 94. ISU Abxis Business Overview Table 95. ISU Abxis Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. ISU Abxis Neurometabolic Disorders Product Portfolio Table 97. ISU Abxis Recent Development Table 98. JCR Pharmaceuticals Company Information Table 99. JCR Pharmaceuticals Business Overview Table 100. JCR Pharmaceuticals Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 102. JCR Pharmaceuticals Recent Development Table 103. Lixte Biotechnology Company Information Table 104. Lixte Biotechnology Business Overview Table 105. Lixte Biotechnology Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Lixte Biotechnology Neurometabolic Disorders Product Portfolio Table 107. Lixte Biotechnology Recent Development Table 108. Neuraltus Pharmaceuticals Company Information Table 109. Neuraltus Pharmaceuticals Business Overview Table 110. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 112. Neuraltus Pharmaceuticals Recent Development Table 113. Pharming Group Company Information Table 114. Pharming Group Business Overview Table 115. Pharming Group Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Pharming Group Neurometabolic Disorders Product Portfolio Table 117. Pharming Group Recent Development Table 118. Protalix Company Information Table 119. Protalix Business Overview Table 120. Protalix Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Protalix Neurometabolic Disorders Product Portfolio Table 122. Protalix Recent Development Table 123. Protalix BioTherapeutics Company Information Table 124. Protalix BioTherapeutics Business Overview Table 125. Protalix BioTherapeutics Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio Table 127. Protalix BioTherapeutics Recent Development Table 128. Shire Company Information Table 129. Shire Business Overview Table 130. Shire Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Shire Neurometabolic Disorders Product Portfolio Table 132. Shire Recent Development Table 133. UAB Proforma Company Information Table 134. UAB Proforma Business Overview Table 135. UAB Proforma Neurometabolic Disorders Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. UAB Proforma Neurometabolic Disorders Product Portfolio Table 137. UAB Proforma Recent Development Table 138. North America Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Neurometabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Neurometabolic Disorders Market Share by Country (2021-2026) Table 141. North America Neurometabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Neurometabolic Disorders Market Share Forecast by Country (2027-2032) Table 143. Europe Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Neurometabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Neurometabolic Disorders Market Share by Country (2021-2026) Table 146. Europe Neurometabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Neurometabolic Disorders Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Neurometabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Neurometabolic Disorders Market Share by Country (2021-2026) Table 151. Asia-Pacific Neurometabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Neurometabolic Disorders Market Share Forecast by Country (2027-2032) Table 153. Latin America Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Neurometabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Neurometabolic Disorders Market Share by Country (2021-2026) Table 156. Latin America Neurometabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Neurometabolic Disorders Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Neurometabolic Disorders Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Neurometabolic Disorders Market Share by Country (2021-2026) Table 161. Middle East & Africa Neurometabolic Disorders Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Neurometabolic Disorders Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Neurometabolic Disorders Product Image Figure 3. Global Neurometabolic Disorders Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neurometabolic Disorders Market Size (2021-2032) & (US$ Million) Figure 5. Global Neurometabolic Disorders Market Share by Region: 2025 VS 2032 Figure 6. Global Neurometabolic Disorders Market Share by Region (2021-2032) Figure 7. North America Neurometabolic Disorders Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Neurometabolic Disorders Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Neurometabolic Disorders Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Neurometabolic Disorders Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Neurometabolic Disorders Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Pompe Disease Image Figure 13. Global Pompe Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Mucopolysaccharidosis VI Image Figure 15. Global Mucopolysaccharidosis VI Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Gaucher’s Disease Image Figure 17. Global Gaucher’s Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Fabry Disease Image Figure 19. Global Fabry Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Other Image Figure 21. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Neurometabolic Disorders Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Neurometabolic Disorders Market Share by Type 2025 VS 2032 Figure 24. North America Neurometabolic Disorders Market Size Share by Type (2021-2032) Figure 25. Europe Neurometabolic Disorders Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Neurometabolic Disorders Market Size Share by Type (2021-2032) Figure 27. Latin America Neurometabolic Disorders Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Neurometabolic Disorders Market Size Share by Type (2021-2032) Figure 29. Oral Image Figure 30. Global Oral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Parenteral Image Figure 32. Global Parenteral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Neurometabolic Disorders Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neurometabolic Disorders Market Share by Application 2025 VS 2032 Figure 35. North America Neurometabolic Disorders Market Size Share by Application (2021-2032) Figure 36. Europe Neurometabolic Disorders Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Neurometabolic Disorders Market Size Share by Application (2021-2032) Figure 38. Latin America Neurometabolic Disorders Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Neurometabolic Disorders Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Neurometabolic Disorders Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Neurometabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Neurometabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Neurometabolic Disorders Market Share by Country (2021-2032) Figure 45. Europe Neurometabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Neurometabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neurometabolic Disorders Market Share by Country (2021-2032) Figure 48. Asia-Pacific Neurometabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Neurometabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Neurometabolic Disorders Market Share by Country (2021-2032) Figure 51. Latin America Neurometabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Neurometabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Neurometabolic Disorders Market Share by Country (2021-2032) Figure 54. Middle East & Africa Neurometabolic Disorders Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Neurometabolic Disorders Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Neurometabolic Disorders Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Pompe Disease
  • Mucopolysaccharidosis VI
  • Gaucher’s Disease
  • Fabry Disease
  • Other
Applications
  • Oral
  • Parenteral
Companies covered
  • Amicus
  • Amicus Therapeutics
  • Biomarin
  • Biosidus
  • Dong-A Socio Group
  • ExSAR Corporation
  • Genzyme
  • Greencross
  • Greenovation Biotech
  • ISU Abxis
  • JCR Pharmaceuticals
  • Lixte Biotechnology
  • Neuraltus Pharmaceuticals
  • Pharming Group
  • Protalix
  • Protalix BioTherapeutics
  • Shire
  • UAB Proforma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Neurometabolic Disorders Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Neurometabolic Disorders Market Size by Region (2021-2032)
  5. 1.4.1 Global Neurometabolic Disorders Market Size by Region (2021-2026)
  6. 1.4.2 Global Neurometabolic Disorders Market Size by Region (2027-2032)
  7. 1.5 Key Regions Neurometabolic Disorders Market Size (2021-2032)
  8. 1.5.1 North America Neurometabolic Disorders Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Neurometabolic Disorders Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Neurometabolic Disorders Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Neurometabolic Disorders Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Neurometabolic Disorders Market Size Growth Rate (2021-2032)
2 Neurometabolic Disorders Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Pompe Disease
  3. 2.1.2 Mucopolysaccharidosis VI
  4. 2.1.3 Gaucher’s Disease
  5. 2.1.4 Fabry Disease
  6. 2.1.5 Other
  7. 2.2 Global Neurometabolic Disorders Market Size by Type
  8. 2.2.1 Global Neurometabolic Disorders Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Neurometabolic Disorders Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Neurometabolic Disorders Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Neurometabolic Disorders Market Size by Regions
  12. 2.3.1 North America Neurometabolic Disorders Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Neurometabolic Disorders Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Neurometabolic Disorders Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Type (2021-2026)
3 Neurometabolic Disorders Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Oral
  3. 3.1.2 Parenteral
  4. 3.2 Global Neurometabolic Disorders Market Size by Application
  5. 3.2.1 Global Neurometabolic Disorders Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Neurometabolic Disorders Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Neurometabolic Disorders Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Neurometabolic Disorders Market Size by Regions
  9. 3.3.1 North America Neurometabolic Disorders Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Neurometabolic Disorders Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Neurometabolic Disorders Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Neurometabolic Disorders Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Neurometabolic Disorders Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Neurometabolic Disorders Industry Trends
  2. 4.2 Neurometabolic Disorders Industry Drivers
  3. 4.3 Neurometabolic Disorders Industry Opportunities and Challenges
  4. 4.4 Neurometabolic Disorders Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Neurometabolic Disorders Revenue (2021-2026)
  2. 5.2 Global Neurometabolic Disorders Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Neurometabolic Disorders Key Company Headquarters & Area Served
  4. 5.4 Global Neurometabolic Disorders Company, Product Type & Application
  5. 5.5 Global Neurometabolic Disorders Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Neurometabolic Disorders Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Neurometabolic Disorders Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Neurometabolic Disorders Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Amicus
  2. 6.1.1 Amicus Company Information
  3. 6.1.2 Amicus Business Overview
  4. 6.1.3 Amicus Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Amicus Neurometabolic Disorders Product Portfolio
  6. 6.1.5 Amicus Recent Developments
  7. 6.2 Amicus Therapeutics
  8. 6.2.1 Amicus Therapeutics Company Information
  9. 6.2.2 Amicus Therapeutics Business Overview
  10. 6.2.3 Amicus Therapeutics Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio
  12. 6.2.5 Amicus Therapeutics Recent Developments
  13. 6.3 Biomarin
  14. 6.3.1 Biomarin Company Information
  15. 6.3.2 Biomarin Business Overview
  16. 6.3.3 Biomarin Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Biomarin Neurometabolic Disorders Product Portfolio
  18. 6.3.5 Biomarin Recent Developments
  19. 6.4 Biosidus
  20. 6.4.1 Biosidus Company Information
  21. 6.4.2 Biosidus Business Overview
  22. 6.4.3 Biosidus Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Biosidus Neurometabolic Disorders Product Portfolio
  24. 6.4.5 Biosidus Recent Developments
  25. 6.5 Dong-A Socio Group
  26. 6.5.1 Dong-A Socio Group Company Information
  27. 6.5.2 Dong-A Socio Group Business Overview
  28. 6.5.3 Dong-A Socio Group Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio
  30. 6.5.5 Dong-A Socio Group Recent Developments
  31. 6.6 ExSAR Corporation
  32. 6.6.1 ExSAR Corporation Company Information
  33. 6.6.2 ExSAR Corporation Business Overview
  34. 6.6.3 ExSAR Corporation Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio
  36. 6.6.5 ExSAR Corporation Recent Developments
  37. 6.7 Genzyme
  38. 6.7.1 Genzyme Company Information
  39. 6.7.2 Genzyme Business Overview
  40. 6.7.3 Genzyme Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Genzyme Neurometabolic Disorders Product Portfolio
  42. 6.7.5 Genzyme Recent Developments
  43. 6.8 Greencross
  44. 6.8.1 Greencross Company Information
  45. 6.8.2 Greencross Business Overview
  46. 6.8.3 Greencross Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Greencross Neurometabolic Disorders Product Portfolio
  48. 6.8.5 Greencross Recent Developments
  49. 6.9 Greenovation Biotech
  50. 6.9.1 Greenovation Biotech Company Information
  51. 6.9.2 Greenovation Biotech Business Overview
  52. 6.9.3 Greenovation Biotech Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio
  54. 6.9.5 Greenovation Biotech Recent Developments
  55. 6.10 ISU Abxis
  56. 6.10.1 ISU Abxis Company Information
  57. 6.10.2 ISU Abxis Business Overview
  58. 6.10.3 ISU Abxis Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 ISU Abxis Neurometabolic Disorders Product Portfolio
  60. 6.10.5 ISU Abxis Recent Developments
  61. 6.11 JCR Pharmaceuticals
  62. 6.11.1 JCR Pharmaceuticals Company Information
  63. 6.11.2 JCR Pharmaceuticals Business Overview
  64. 6.11.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
  66. 6.11.5 JCR Pharmaceuticals Recent Developments
  67. 6.12 Lixte Biotechnology
  68. 6.12.1 Lixte Biotechnology Company Information
  69. 6.12.2 Lixte Biotechnology Business Overview
  70. 6.12.3 Lixte Biotechnology Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Lixte Biotechnology Neurometabolic Disorders Product Portfolio
  72. 6.12.5 Lixte Biotechnology Recent Developments
  73. 6.13 Neuraltus Pharmaceuticals
  74. 6.13.1 Neuraltus Pharmaceuticals Company Information
  75. 6.13.2 Neuraltus Pharmaceuticals Business Overview
  76. 6.13.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
  78. 6.13.5 Neuraltus Pharmaceuticals Recent Developments
  79. 6.14 Pharming Group
  80. 6.14.1 Pharming Group Company Information
  81. 6.14.2 Pharming Group Business Overview
  82. 6.14.3 Pharming Group Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Pharming Group Neurometabolic Disorders Product Portfolio
  84. 6.14.5 Pharming Group Recent Developments
  85. 6.15 Protalix
  86. 6.15.1 Protalix Company Information
  87. 6.15.2 Protalix Business Overview
  88. 6.15.3 Protalix Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Protalix Neurometabolic Disorders Product Portfolio
  90. 6.15.5 Protalix Recent Developments
  91. 6.16 Protalix BioTherapeutics
  92. 6.16.1 Protalix BioTherapeutics Company Information
  93. 6.16.2 Protalix BioTherapeutics Business Overview
  94. 6.16.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
  96. 6.16.5 Protalix BioTherapeutics Recent Developments
  97. 6.17 Shire
  98. 6.17.1 Shire Company Information
  99. 6.17.2 Shire Business Overview
  100. 6.17.3 Shire Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Shire Neurometabolic Disorders Product Portfolio
  102. 6.17.5 Shire Recent Developments
  103. 6.18 UAB Proforma
  104. 6.18.1 UAB Proforma Company Information
  105. 6.18.2 UAB Proforma Business Overview
  106. 6.18.3 UAB Proforma Neurometabolic Disorders Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 UAB Proforma Neurometabolic Disorders Product Portfolio
  108. 6.18.5 UAB Proforma Recent Developments
7 North America
  1. 7.1 North America Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Neurometabolic Disorders Market Size by Country (2021-2026)
  3. 7.3 North America Neurometabolic Disorders Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Neurometabolic Disorders Market Size by Country (2021-2026)
  3. 8.3 Europe Neurometabolic Disorders Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Neurometabolic Disorders Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Neurometabolic Disorders Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Neurometabolic Disorders Market Size by Country (2021-2026)
  3. 10.3 South America Neurometabolic Disorders Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neurometabolic Disorders Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Neurometabolic Disorders Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Neurometabolic Disorders Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst